OPEN END TURBO LONG - MADRIGAL PHARMACEUTICALS | Market Closed - Bid/Ask 10:17:07 2024-07-16 EDT | After market 14:22:58 | |||
| 3.72 EUR | +9.41% |
|
3.39 | -8.87% |
| Current month | -1.73% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about MADRIGAL PHARMACEUTICALS, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 3.72 | +9.41% |
| 24-07-15 | 3.4 | -8.85% |
| 24-07-12 | 3.73 | -13.05% |
| 24-07-11 | 4.29 | +9.16% |
| 24-07-10 | 3.93 | -12.67% |
Delayed Quote Börse Stuttgart
Last update July 16, 2024 at 10:17 am
More quotesStatic data
| Product type | Warrant Knock-Out senza Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | MADRIGAL PHARMACEUTICALS, INC. |
| Issuer | Morgan Stanley |
| WKN | MG6KXB |
| ISIN | DE000MG6KXB3 |
| Date issued | 2024-06-26 |
| Strike | 251.4 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.26 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.66 € |
|---|---|
| Lowest since issue | 2.42 € |
| Spread | 0.26 € |
| Spread % | 7.41% |
Company Profile
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâs clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Sector
-
Consensus: Madrigal Pharmaceuticals, Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
280
USD
Average target price
365.3
USD
Spread / Average Target
+30.50%
- Stock Market
- Certificates
- Certificat
